ScholarLens Back to search
2006•BloodRequires access

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Rudolf Weide, Georg Heß, H. F. Koeppler, Jochen Heymanns, Joerg Thomalla, Ali Aldaoud, Christoph J. Losem, Stefan Schmitz, Ursula Haak, Christoph H. Huber, Michael Unterhalt, Wolfgang Hiddemann, Martin H. Dreyling

Open publisher page 1 citations

Abstract

Abstract Purpose: Bendamustine is a new anti-lymphoma agent with promising activity. Based on a preceeding phase I study the current trial explored Bendamustine in combination with Mitoxantrone and Rituximab (BMR) in patients with relapsed or refractory indolent lymphomas. Patients and Methods: Patients with relapsed or refractory symptomatic stage III/IV indolent lymphomas with or without prior treatment with Rituximab were eligible. Therapy consisted of Bendamustine 90 mg/m2 days 1+2, Mitoxantrone 10 mg/m2 day 1, Rituximab 375 mg/m2 day 8. Treatment was repeated on day 29 for a total of 4 cycles. Results: Between 04/03 and 07/04 62 patients were recruited from 24 participating institutions, 40% of whom had received prior Rituximab therapy. Median age was 67 years (40–83). Lymphoma subtypes were 30 follicular (FL), 18 mantle cell (MCL), 4 B-CLL with plasmacytic differentiation, 3 lymphoplasmacytic (LPL), 3 marginal zone (MZL), 2 diffuse large B-cell (DLBCL), 1 high grade lymphoma not otherwise specified and 1 hairy cell leukemia. The overall response rate (ORR) was 88% with 36% CR and 53% PR. ORR in Rituximab pretreated patients was 75% (38% CR, 38% PR). After a median observation time of 17 months (1 – 33), the estimated median progression free survival is 19 months. Treatment related toxicities of grade 3/4 comprized a reversible myelosuppression (10 % anemia, 78 % leukocytopenia, 46 % granulocytopenia, 16 % thrombocytopenia). However, unexpected hospitalisations were necessary after 10 of 231 cycles (4%) only. Conclusion: BMR is a very effective new outpatient immuno-chemotherapy with low toxicity for patients with relapsed/refractory indolent lymphoma. Response rates All patients FL MCL pretreated with Rituximab n 62 30 18 25 end of therapy without staging 3 3 0 1 evaluable patients 59 27 18 24 CR 21 (36%) 13 (48%) 6 (33%) 9 (38%) PR 31 (53%) 12 (44%) 8 (44%) 9 (38%) MR 1 (2%) 0 (0%) 1 (6%) 1 (4%) SD 0 (0%) 0 (0%) 0 (0%) 0 (0%) PD 6 (10%) 2 (7%) 3 (17%) 5 (21%) EX 0 (0%) 0 (0%) 0 (0%) 0 (0%) CR+PR 52 (88%) 25 (93%) 14 (78%) 18 (75%) Figure Figure

About this research paper

What this paper is about

Abstract Purpose: Bendamustine is a new anti-lymphoma agent with promising activity. Based on a preceeding phase I study the current trial explored Bendamustine in combination with Mitoxantrone and Rituximab (BMR) in patients with relapsed or refractory indolent lymphomas. Patients and Methods: Patients with relapsed or refractory symptomatic stage III/IV indolent lymphomas with or without prior treatment with Rituximab were eligible. Therapy consisted of Bendamustine 90 mg/m2 days 1+2, Mitoxantrone 10 mg/m2 day 1, Rituximab 375 mg/m2 day 8. Treatment was repeated on day 29 for a total of 4 cycles. Results: Between 04/03 and 07/04 62 patients were recruited from 24 participating institutions, 40% of whom had received prior Rituximab therapy. Median age was 67 years (40–83). Lymphoma subtypes were 30 follicular (FL), 18 mantle cell (MCL), 4 B-CLL with plasmacytic differentiation, 3 lymphoplasmacytic (LPL), 3 marginal zone (MZL), 2 diffuse large B-cell (DLBCL), 1 high grade lymphoma not otherwise specified and 1 hairy cell leukemia. The overall response rate (ORR) was 88% with 36% CR and 53% PR. ORR in Rituximab pretreated patients was 75% (38% CR, 38% PR). After a median observation time of 17 months (1 – 33), the estimated median progression free survival is 19 months. Treatment related toxicities of grade 3/4 comprized a reversible myelosuppression (10 % anemia, 78 % leukocytopenia, 46 % granulocytopenia, 16 % thrombocytopenia). However, unexpected hospitalisations were necessary after 10 of 231 cycles (4%) only. Conclusion: BMR is a very effective new outpatient immuno-chemotherapy with low toxicity for patients with relapsed/refractory indolent lymphoma. Response rates All patients FL MCL pretreated with Rituximab n 62 30 18 25 end of therapy without staging 3 3 0 1 evaluable patients 59 27 18 24 CR 21 (36%) 13 (48%) 6 (33%) 9 (38%) PR 31 (53%) 12 (44%) 8 (44%) 9 (38%) MR 1 (2%) 0 (0%) 1 (6%) 1 (4%) SD 0 (0%) 0 (0%) 0 (0%) 0 (0%) PD 6 (10%) 2 (7%) 3 (17%) 5 (21%) EX 0 (0%) 0 (0%) 0 (0%) 0 (0%) CR+PR 52 (88%) 25 (93%) 14 (78%) 18 (75%) Figure Figure

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Abstract Purpose: Bendamustine is a new anti-lymphoma agent with promising activity. Based on a preceeding phase I study the current trial explored Bendamustine in combination with Mitoxantrone and Rituximab (BMR) in patients with relapsed or refractory indolent lymphomas. Patients and Methods: Patients with relapsed or refractory symptomatic stage III/IV indolent lymphomas with or without prior treatment with Rituximab were eligible. Therapy consisted of Bendamustine 90 mg/m2 days 1+2, Mitoxantrone 10 mg/m2 day 1, Rituximab 375 mg/m2 day 8. Treatment was repeated on day 29 for a total of 4 cycles. Results: Between 04/03 and 07/04 62 patients were recruited from 24 participating institutions, 40% of whom had received prior Rituximab therapy. Median age was 67 years (40–83). Lymphoma subtypes were 30 follicular (FL), 18 mantle cell (MCL), 4 B-CLL with plasmacytic differentiation, 3 lymphoplasmacytic (LPL), 3 marginal zone (MZL), 2 diffuse large B-cell (DLBCL), 1 high grade lymphoma not otherwise specified and 1 hairy cell leukemia. The overall response rate (ORR) was 88% with 36% CR and 53% PR. ORR in Rituximab pretreated patients was 75% (38% CR, 38% PR). After a median observation time of 17 months (1 – 33), the estimated median progression free survival is 19 months. Treatment related toxicities of grade 3/4 comprized a reversible myelosuppression (10 % anemia, 78 % leukocytopenia, 46 % granulocytopenia, 16 % thrombocytopenia). However, unexpected hospitalisations were necessary after 10 of 231 cycles (4%) only. Conclusion: BMR is a very effective new outpatient immuno-chemotherapy with low toxicity for patients with relapsed/refractory indolent lymphoma. Response rates All patients FL MCL pretreated with Rituximab n 62 30 18 25 end of therapy without staging 3 3 0 1 evaluable patients 59 27 18 24 CR 21 (36%) 13 (48%) 6 (33%) 9 (38%) PR 31 (53%) 12 (44%) 8 (44%) 9 (38%) MR 1 (2%) 0 (0%) 1 (6%) 1 (4%) SD 0 (0%) 0 (0%) 0 (0%) 0 (0%) PD 6 (10%) 2 (7%) 3 (17%) 5 (21%) EX 0 (0%) 0 (0%) 0 (0%) 0 (0%) CR+PR 52 (88%) 25 (93%) 14 (78%) 18 (75%) Figure Figure

Key concepts: Bendamustine, Rituximab, Medicine, Leukocytopenia, Mitoxantrone, Internal medicine, Follicular lymphoma, Gastroenterology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG). — Research Paper | ScholarLens